Pardes is a clinical-stage biopharmaceutical company created by and for this moment to solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to develop novel drugs while reimagining the patient journey to access these medicines.
04/15/2022 2:58 AMEDT
Report of unscheduled material events or corporate event
|8-K||EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT|
Quarterly report which provides a continuing view of a company's financial position
|10-Q||EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA|
Form of prospectus reflecting facts events constituting substantive change from last form
Send us an investor-related question using the form below.